Editorial Perspectives On Patient Recruitment

  1. One Person Closer Attempts To Inspire Doctors & Patients 2/22/2018

    Patient recruitment remains a challenge for most companies performing clinical research. One of the factors that will lead to many individuals being completely unaware of trials is the limited communication between doctors and patients about opportunities to participate in clinical studies.

  2. Will A New Engagement Tool Finally Solve The Patient Recruitment Problem? 2/14/2018

    Getting new treatments to patients is a long and costly endeavor. Most drugs take upward of eight years and billions of dollars to receive regulatory approval. One of the biggest problems sponsor companies face when trying to launch a Phase 3 trial is finding enough patients to take part in the study.

  3. The Father And CEO Who Climbed A Mountain To Raise Awareness 12/21/2017

    How far would most CEOs go to raise awareness of the diseases they are attempting to treat? Tim Miller, CEO of Abeona Therapeutics, climbed more than 14,000 feet to the top of Mt. Rainier to raise awareness for Sanfilippo Syndrome, a rare and deadly genetic disease that impacts children.

  4. Physicians And The Patient Recruitment Problem 12/18/2017

    The world of patient recruitment is changing. Whereas pharma and CROs once relied almost entirely on investigator sites to recruit study participants, patient advocacy groups, social media, and new technologies are creating opportunities to access needed patients. But in doing so, are companies running the risk of further alienating treating physicians?

  5. Beat AML Utilizes Innovative Master Trial Configuration 12/15/2017

    Acute myeloid leukemia (AML) is a cancer that develops in bone marrow where new blood cells are created. It quickly moves into the blood, where it can be fatal in a matter of months. A new trial using a Master Trial configuration will provide hope for patients.

  6. J&J Announces First Efficacy Study For HIV-1 Preventive Vaccine 12/6/2017

    On the eve of World AIDS Day 2017, the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH) have joined forces with Johnson & Johnson (J&J) to advance a potential “global vaccine” that could prevent a wide range of viral strains responsible for the world’s HIV pandemic.

  7. Trial Aims To Kill Cancer Without Chemotherapy Side Effects 11/20/2017

    Getting a new oncology drug to patients involves navigating an obstacle course of costs, timelines, safety and effectiveness data, and regulations. Starting the clinical process with a molecule that has already been proven to kill cancer cells and be safe for patients will eliminate much of the risk. That is exactly what NanOlogy, a clinical-stage oncology company, is attempting to do.

  8. Can GAP Double The Number Of Patients In Alzheimer's Trials? 11/13/2017

    According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than 30 percent of total trial time is spent simply recruiting patients. Those issues are present in all therapeutic areas, including Alzheimer’s disease. To mitigate these problems, cut the time of trials, and get needed medicines to patients faster, the Global Alzheimer’s Platform (GAP) Foundation is implementing a new model that promises to increase patient participation in Alzheimer’s research.

  9. Clinical News Roundup: FDA Awards Funding To Pediatric Clinical Trials 11/10/2017

    Clinical news roundup for the week of November 6th with information on FDA funding pediatric trials, clinical trials for heroin addicts, Marken’s home delivery app, Seeker’s patient enrollment portal, and minority recruitment in trials.

  10. How Poor Communication, Patient Recruitment Plague Clinical Trials 11/6/2017

    Two issues continue to be a headache for those working in the clinical space: patient recruitment and communication. New technologies, including social media, seem to offer a glimmer of hope to getting more patients involved in trials. Unfortunately, the problem of poor communication between sponsors, CROs, and sites is an issue still in need of novel solutions. In this Q&A, Mary Rose Keller, VP of clinical operations for Heron Therapeutics, shares her insights.